DR30318(DR30318) - 药物靶点：CD3 x CLDN18.2 x albumin_在研适应症：实体瘤_专利_临床

概要

基本信息

药物类型

纳米抗体、双特异性T细胞结合器

别名-

靶点

CD3 x CLDN18.2 x albumin

作用机制

CD3刺激剂(T细胞表面糖蛋白CD3复合体刺激剂)、CLDN18.2抑制剂(Claudin 18.2蛋白抑制剂)、albumin调节剂(血清白蛋白调节剂)

治疗领域

肿瘤

在研适应症

实体瘤

非在研适应症-

原研机构

浙江道尔生物科技有限公司

在研机构

浙江道尔生物科技有限公司

非在研机构-

最高研发阶段临床申请

首次获批日期-

最高研发阶段(中国)临床申请

特殊审评-

登录后查看时间轴

关联

100 项与 DR30318 相关的临床结果

登录后查看更多信息

100 项与 DR30318 相关的转化医学

登录后查看更多信息

100 项与 DR30318 相关的专利（医药）

登录后查看更多信息

1

项与 DR30318 相关的文献（医药）

Cancer Immunology, Immunotherapy

DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy

Article

作者: Liu, Yuanyuan ; Zhou, Zhenxing ; Ou, Fengting ; Zong, Sidou ; Yu, Lushan ; Sheng, Shimei ; Duan, Wenwen ; Huang, Yanshan ; Zhang, Xin ; Ma, Zhe ; Yao, Gaofeng ; Li, Changkui ; Dahar, Maha Raja

AbstractBackgroundClaudin 18.2 (CLDN18.2) is a highly anticipated target for solid tumor therapy, especially in advanced gastric carcinoma and pancreatic carcinoma. The T cell engager targeting CLDN18.2 represents a compelling strategy for enhancing anti-cancer efficacy.MethodsBased on the in-house screened anti-CLDN18.2 VHH, we have developed a novel tri-specific T cell engager targeting CLDN18.2 for gastric and pancreatic cancer immunotherapy. This tri-specific antibody was designed with binding to CLDN18.2, human serum albumin (HSA) and CD3 on T cells.ResultsThe DR30318 demonstrated binding affinity to CLDN18.2, HSA and CD3, and exhibited T cell-dependent cellular cytotoxicity (TDCC) activity in vitro. Pharmacokinetic analysis revealed a half-life of 22.2–28.6 h in rodents and 41.8 h in cynomolgus monkeys, respectively. The administration of DR30318 resulted in a slight increase in the levels of IL-6 and C-reactive protein (CRP) in cynomolgus monkeys. Furthermore, after incubation with human PBMCs and CLDN18.2 expressing cells, DR30318 induced TDCC activity and the production of interleukin-6 (IL-6) and interferon-gamma (IFN-γ). Notably, DR30318 demonstrated significant tumor suppression effects on gastric cancer xenograft models NUGC4/hCLDN18.2 and pancreatic cancer xenograft model BxPC3/hCLDN18.2 without affecting the body weight of mice.

100 项与 DR30318 相关的药物交易

登录后查看更多信息